Nath Bio-Genes (India) Balance Sheet Health
Finanzielle Gesundheit Kriterienprüfungen 4/6
Nath Bio-Genes (India) hat ein Gesamteigenkapital von ₹6.4B und eine Gesamtverschuldung von ₹1.3B, wodurch sich der Verschuldungsgrad auf 19.9% beläuft. Die Gesamtaktiva und Gesamtpassiva betragen ₹8.3B bzw. ₹1.9B. Nath Bio-Genes (India) Das EBIT des Unternehmens beträgt ₹461.8M, so dass der Zinsdeckungsgrad 5.5 beträgt. Das Unternehmen verfügt über Barmittel und kurzfristige Anlagen in Höhe von ₹20.8M.
Wichtige Informationen
19.9%
Verhältnis von Schulden zu Eigenkapital
₹1.27b
Verschuldung
| Zinsdeckungsgrad | 5.5x |
| Bargeld | ₹20.77m |
| Eigenkapital | ₹6.40b |
| Gesamtverbindlichkeiten | ₹1.88b |
| Gesamtvermögen | ₹8.28b |
Jüngste Berichte zur Finanzlage
These 4 Measures Indicate That Nath Bio-Genes (India) (NSE:NATHBIOGEN) Is Using Debt Reasonably Well
Jun 27
Nath Bio-Genes (India) (NSE:NATHBIOGEN) Seems To Use Debt Quite Sensibly
Aug 05We Think Nath Bio-Genes (India) (NSE:NATHBIOGEN) Is Taking Some Risk With Its Debt
Aug 27Nath Bio-Genes (India) (NSE:NATHBIOGEN) Has A Pretty Healthy Balance Sheet
Feb 24Is Nath Bio-Genes (India) (NSE:NATHBIOGEN) A Risky Investment?
Feb 28These 4 Measures Indicate That Nath Bio-Genes (India) (NSE:NATHBIOGEN) Is Using Debt Reasonably Well
Nov 26Recent updates
Here's Why Shareholders Should Examine Nath Bio-Genes (India) Limited's (NSE:NATHBIOGEN) CEO Compensation Package More Closely
Aug 11Nath Bio-Genes (India)'s (NSE:NATHBIOGEN) Solid Earnings May Rest On Weak Foundations
Jul 31Nath Bio-Genes (India) Limited (NSE:NATHBIOGEN) Shares Fly 34% But Investors Aren't Buying For Growth
Jul 02These 4 Measures Indicate That Nath Bio-Genes (India) (NSE:NATHBIOGEN) Is Using Debt Reasonably Well
Jun 27Nath Bio-Genes (India) (NSE:NATHBIOGEN) Has More To Do To Multiply In Value Going Forward
Apr 05Returns On Capital At Nath Bio-Genes (India) (NSE:NATHBIOGEN) Have Hit The Brakes
Oct 24Nath Bio-Genes (India) (NSE:NATHBIOGEN) Seems To Use Debt Quite Sensibly
Aug 05Nath Bio-Genes (India) (NSE:NATHBIOGEN) Has Some Way To Go To Become A Multi-Bagger
Jun 07Some Investors May Be Worried About Nath Bio-Genes (India)'s (NSE:NATHBIOGEN) Returns On Capital
Feb 11We Think Nath Bio-Genes (India) (NSE:NATHBIOGEN) Is Taking Some Risk With Its Debt
Aug 27Nath Bio-Genes (India)'s (NSE:NATHBIOGEN) Returns On Capital Not Reflecting Well On The Business
Jun 19Nath Bio-Genes (India) (NSE:NATHBIOGEN) Has A Pretty Healthy Balance Sheet
Feb 24Returns On Capital Signal Tricky Times Ahead For Nath Bio-Genes (India) (NSE:NATHBIOGEN)
May 27Is Nath Bio-Genes (India) (NSE:NATHBIOGEN) A Risky Investment?
Feb 28The Trends At Nath Bio-Genes (India) (NSE:NATHBIOGEN) That You Should Know About
Feb 07Declining Stock and Decent Financials: Is The Market Wrong About Nath Bio-Genes (India) Limited (NSE:NATHBIOGEN)?
Jan 19The Nath Bio-Genes (India) (NSE:NATHBIOGEN) Share Price Is Up 149% And Shareholders Are Boasting About It
Jan 01Why Nath Bio-Genes (India)'s (NSE:NATHBIOGEN) CEO Pay Matters
Dec 14
These 4 Measures Indicate That Nath Bio-Genes (India) (NSE:NATHBIOGEN) Is Using Debt Reasonably Well
Nov 26Here's What To Make Of Nath Bio-Genes (India)'s (NSE:NATHBIOGEN) Returns On Capital
Nov 05Do Its Financials Have Any Role To Play In Driving Nath Bio-Genes (India) Limited's (NSE:NATHBIOGEN) Stock Up Recently?
Oct 15Nath Bio-Genes (India) Limited (NSE:NATHBIOGEN) Might Not Be As Mispriced As It Looks After Plunging 25%
Sep 24Many Still Looking Away From Nath Bio-Genes (India) Limited (NSE:NATHBIOGEN)
Sep 08Introducing Nath Bio-Genes (India) (NSE:NATHBIOGEN), The Stock That Soared 311% In The Last Five Years
Sep 07Nath Bio-Genes (India) Limited (NSE:NATHBIOGEN) Doing What It Can To Lift Shares
Aug 18Here's What We Think About Nath Bio-Genes (India)'s (NSE:NATHBIOGEN) CEO Pay
Jul 26Analyse der Finanzlage
Kurzfristige Verbindlichkeiten: NATHBIOGENDie kurzfristigen Aktiva des Unternehmens (₹5.2B) übersteigen seine kurzfristigen Passiva (₹1.8B).
Langfristige Verbindlichkeiten: NATHBIOGENDie kurzfristigen Vermögenswerte des Unternehmens (₹5.2B) übersteigen seine langfristigen Verbindlichkeiten (₹68.6M).
Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital
Verschuldungsgrad: NATHBIOGENDie Nettoverschuldung im Verhältnis zum Eigenkapital (19.6%) wird als zufriedenstellend angesehen.
Schulden abbauen: NATHBIOGENDas Verhältnis von Schulden zu Eigenkapital ist in den letzten 5 Jahren von 12.2% auf 19.9% gestiegen.
Schuldendeckung: NATHBIOGENDie Schulden des Unternehmens sind nicht ausreichend durch den operativen Cashflow (8.8%) gedeckt.
Zinsdeckung: NATHBIOGENDie Zinszahlungen für die Schulden des Unternehmens sind durch das EBIT (5.5x Coverage) gut gedeckt.